From Phase I to Phase II: Leveraging Early Clinical Data to Inform the Next Stage of Radiopharmaceutical Development

1:30 pm - Thursday 3rd December 2026

  • Sharing Phase I clinical findings and evaluating the key efficacy, safety and translational signals emerging from early development
  • Understanding how early clinical data can be used to refine patient selection, endpoint strategy and study design ahead of Phase II
  • Exploring the operational, clinical and regulatory challenges associated with progressing a radiopharmaceutical programme beyond first-in-human evaluation

Speakers:

Chief Executive Officer
Oncoinvent AS